Poland Integrated Medicines Management (PL-IMM) - Study Assessing the Provision of Complex Clinical Pharmacy Services to Hospitalized Patients

NCT07159932 | Not Yet Recruiting

• 1 other identifier: KB 47O/2O23N
• Study Type: interventional
• Target: 610
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the study is to assess whether the involvement of a clinical pharmacist in patient care at every stage of hospitalization, from admission to discharge, will improve the quality of healthcare services provided in clinical and economic terms. As part of the research study, we will randomly assign you to two different groups. Within one group, a pharmacist will be involved in the process of caring for you throughout your hospital stay. The pharmacist will participate in medical rounds, verify medications upon admission to the hospital, check current test results and medical orders regarding pharmacotherapy, verify medications upon discharge and provide advice on the use of medications. All activities will be carried out in consultation with other medical staff. The aim is to check whether such a model of patient care increases safety and leads to improved pharmacotherapy for patients, and also has a positive effect on patient satisfaction and compliance with therapeutic recommendations. Additionally, the opinion of the medical staff and the economic aspects of this solution will be assessed. Within the second group, you will receive standard care offered by the hospital. In the case of both groups, after the hospitalization is completed, the pharmacist will contact you after 1, 3, 6 months to verify your health condition - he or she will ask about any hospitalizations, complications, side effects, and additional visits to the doctor.

Conditions

Acute Admitted Multimorbid Patients

Keywords

clinical pharmacy; integrated medicines managment; pharmacist interventions; clinical pharmacy services; medicines management; transfer of care; medicines review; medicines reconcilliation; patient education

Outcome Measures

Primary Outcomes (1)

• Additional episodes of care

  incidence of hospital, emergency department and other unscheduled visits after discharge from hospital during the 6 months follow-up period

  1, 3 and 6 months after discharge

Secondary Outcomes (1)

• LoS

  Periprocedural

Other Outcomes (5)

• Interventions

  Periprocedural

• Economy

  from first patient enrollment at hospital admission until the end of 6 month follow-up period of the last patient enrolled

• Patient opinion

  at hospital discharge before patient begins the 6 month follow-up period

Study Arms (2)

Control group

NO INTERVENTION

Standard care during hospital stay, without pharmacist involved

Pharmacist intervention - IMM

EXPERIMENTAL

A pharmacist is included in the multidisciplinary treatment team during the hospital stay

Behavioral: multidisciplinary treatment

Interventions

multidisciplinary treatment BEHAVIORAL

The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug education to the patient before discharge, as well as written drug information

Pharmacist intervention - IMM

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ≥18 years old and an acute admission to the hospital fulfilling at least one of the following criteria:
• taking ≥4 medicines
• taking high risk medicines listed in the medicines reconciliation standard of Polish Society of Clinical Pharmacy (….)
• medicine related admission to the hospital within last 12 months
• chronic kidney or liver disease
• after solid organ transplantation

You may not qualify if:

• age below 18 years old
• pregnancy
• resident of long-term care facility
• unable to express informed consent to participate in the research
• expected survival less than 6 months

Sponsors & Collaborators

• Wroclaw Medical University: lead

Study Sites (1)

Regional Hospital in Wroclaw

Wroclaw, 51 124, Poland

Location

Central Study Contacts

Kamila Urbańczyk, MPharm

CONTACT

0048 71 32 70 427; kamila.urbanczyk@umw.edu.pl

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MPharm

Study Record Dates

• First Submitted: June 24, 2025
• First Posted: September 8, 2025
• Study Start: January 1, 2026
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): December 30, 2027
• Last Updated: September 8, 2025

Record last verified: 2025-06

Locations

PL (1)